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gene expression, and apoptosis. Zn enzymes are involved in nucleic acid metabolism and cellular 72 proliferation, differentiation, and growth (Chesters 1978) . 73
Plasma Zn accounts for only about 0.1 per cent of the total body content. Zn has a rapid turnover, 74
and its level appears to be under close homeostatic control. There is no 'store' for Zn in the 75 conventional sense (Milne et al. 1983 ) and it is present in the body almost exclusively as Zn2+ 76 bound to cellular proteins . 77
Assessment of the Zn nutriture of individuals is complicated by the fact that no generally accepted, 78 sensitive and specific biomarker of serum/plasma Zn status exists (King 1990 ). Although it is true 79 that serum/plasma Zn concentrations decrease within several weeks of the introduction of a diet 80 containing a severely restricted amount of Zn (Baer et al. 1985) , serum/plasma Zn concentrations 81 are generally maintained within the normal range with small or moderate reductions in Zn intake. 82
Moreover, factors unrelated to the level of Zn nutriture, such as recent meals, time of day, infection, 83 tissue catabolism, and pregnancy, can also affect serum/plasma Zn concentrations (King 1990; 84 Hambidge & Krebs 1995). Thus, the serum/plasma Zn concentration may not always be a reliable 85 indicator of an individual's true Zn status (Brown et al. 2002) . Nevertheless a recent systematic 86 review concluded that serum/plasma Zn concentration was responsive to both Zn supplementation 87 and depletion and it remains the most widely used biomarker for Zn (Lowe et al. 2009 ). 88 89 Infants have a relatively high requirement of Zn per unit body weight during a sensitive period of 90 rapid growth and development (Hermoso et al. 2010) . Recommendations for Zn intake during 91 infancy vary widely across Europe, ranging from 1 mg/day up to 5 mg/day (Hermoso et al. 2010) . 92
The EURRECA project attempts to consolidate the basis for the definition of micronutrient 93 requirements across Europe, taking into account relationships among intake, status and health 94 outcomes, in order to harmonise these recommendations (Ashwell et al. 2008 Recommendations Aligned (EURRECA) Network of Excellence that aims to identify the 105 micronutrient requirements for optimal health in European populations (www.eurreca.org). This 106 review was part of a wider review process to identify studies assessing the effect of Zn intake on 107 different outcomes (biomarkers of Zn status and health outcomes). The wider searches were 108 performed of literature published up to and including February 2010, and an updated search was 109 carried out in January 2013. The databases MEDLINE, EMBASE and Cochrane using search terms 110 for "study designs in humans" and "zinc" and "intake". Both indexing and text terms were used and 111 languages included were restricted to those spoken in the EURRECA Network (English, Dutch, 112 French, German, Hungarian, Italian, Norwegian, Polish, Spanish, Greek, and Serbian.). The Ovid 113 MEDLINE search strategy can be found in Table 1 . Reference lists of retrieved articles and 114 published literature reviews were also checked for relevant studies. The procedure for the 115 identification, selection of articles and data extraction is illustrated in Figure 1 . 116
Selection of articles 117
Titles of articles identified from the searches were entered into an EndNote library. Papers were 118 considered eligible for inclusion if they were RCTs, conducted in human infants (aged 0-12 119 months), and studied the effect of supplements, fortified foods or micronutrient intake from natural 120 food sources, and assessed Zn concentrations in serum / plasma. Zn intake was assessed from breast 121 milk, infant formula and food sources (e.g. complementary foods), fortified foods (e.g. fortified 122 formula or cereal) and supplements. 123 Briefly, titles and abstracts of the 10% of the library were screened in duplicate for eligibility by 129 two reviewers and any discrepancies were discussed and resolved before screening the remaining 130 references. Only when both reviewers agreed that titles and abstracts met the inclusion criteria were 131 the articles included. When a title and abstract could not be included with certainty, the full text of 132 the article was obtained and then further evaluated. The remaining 90% was distributed among the 133 two reviewers in even parts. Following the initial screening process, full-text articles were obtained. 134
Further inclusion and exclusion criteria were then applied. Papers were only included in the meta-135 analysis if they were: randomised controlled trials; had an intervention duration of at least 2 weeks; 136 and reported baseline data for all outcome measures. Non-randomised controlled trials, uncontrolled 137 trials or trials reporting insufficient or unclear data were excluded. Data were extracted from each 138 study and organized in a Microsoft Access database file (Microsoft Corp, Redmond, WA). 139 140
Data synthesis 141
When Zn status in serum/plasma was measured at different time points within the same population, 142 we used the measures as different estimations (Bates et al. 1993; I/II). One 143 study reported data from the total of infants included, between males and females separately, and 144 according to age (<11 months and > 11 months) (Sazawal et al. 1996; and it was treated as 145 five estimations within the meta-analysis. One study reported data from two groups of infants 146 (stunted and non stunted) and these were treated as two different estimations (Umeta et al. 2000) . 147
One study reported data from two groups according to the form of Zn supplementation (tablets or 148 liquid) and these were treated as two estimations within the meta analysis (Wessells et al. 2012 ). Of 149 the selected studies, two RCTs were companion papers (Makonnen et al. 2003 I; Sazawal et al. 150 2004) . If dietary intake of Zn (in addition to the intervention) was not reported in the RCTs, we 151 imputed a value of 1.3 mg/day, the mean dietary intake level of the RCTs that did report dietary Zn 152 intake. As mean baseline serum/plasma Zn concentrations were infrequently reported in the RCTs, 153 most of the RCTs assumed no differences in baseline serum/plasma Zn concentrations (n= 12). The influence of Zn intake on serum/plasma Zn concentrations was considered in the overall meta-160 analysis. Other variables were also taken into account as possible effect modifiers. We considered 161 doses of Zn intake (1 to 4 mg, 4.1 to 8 mg, 8.1 to 12 mg, and >12.1 mg), intervention duration (1 to 
Assessment of risk of bias in included studies 176
Risk of bias was assessed in order to evaluate the quality of the studies included. The following 177 indicators of internal validity specific to the RCT methodology were collected during data 178 extraction: 1) method of sequence generation and 2) adequate allocation, 3) blinding, 4) number of 179 participants at start, dropouts and dropout reasons, 5) outcome data complete, 6) funder adequate 7) 180 other potential funding bias . Based on these indicators, two reviewers assessed the overall risk of 181 bias. Disagreements were resolved by discussion. The criteria for judging these indicators were 182 adapted from the Cochrane Handbook for Systematic Reviews (Higgins & Green 2009) ( Table 2) differences was a formal meta-analysis (Greenland 1998) . A random-effects model was considered 197 to be more appropriate than a fixed-effects model. We used the DerSimonian and Laird's 198 (DerSimonian & Laird 1986) to pool the estimates of betas across studies. Under this model, the 199 pooled effect was the beta in the status parameter (serum / plasma), for an increment of 1 unit in Zn 200 intake. A pooled beta estimate was calculated as a weighted average of the beta reported in each 201 study. 202
The formula we used to estimate the weighted effect size was (Hedges 1982) : 203
where β pooled is the pooled estimate of the beta in status parameters; the weight (wi) of each study 205 was computed as: 206
where V is the variance of each study and ‫ح‬ ² is the inter study variance. 208
Besides this, we calculated a 95% confidence interval for the pooled estimated of effect size: 209
where SE is the standard error of the pooled estimate (Greenland 1998) . 211 212 A test of heterogeneity was calculated, estimating Q statistics, which follows a chi-square 213 distribution with degrees of freedom n-1, n being the number of studies included in the analysis. 214
The I² Index measures the extent of the heterogeneity. A low P value for this statistic (lower than 215 0.05) indicates the presence of heterogeneity, which somewhat compromises the validity of the 216 pooled estimates (Takkouche et al. 1999 ). Because significant heterogeneity was clearly evident in 217 the pooled beta estimates for all studies combined in each outcome, we evaluated potential sources 218 of heterogeneity by linear meta-regressions (Greenland 1998 ). We fitted a meta-regression using the 219 duration of the intervention, the doses of Zn intake, the risk of bias, and the nutritional situation as 220 independent variables. The betas of the different status parameters according to Zn intake were used 221 as the dependent variable. Statistical differences in multivariate adjusted mean beta values between 222 each possible heterogeneity sources were determined by ANCOVA. Additionally we carried out 223 0.05, 0.12). However, a substantial heterogeneity was present in the analyses (I² for status = 98%). 271
In order to investigate which variables may be potential effect modifiers, we performed a meta-272 regression ( Table 4 ). The effect of Zn intake on serum/plasma Zn status changed depending on the 273 duration of the intervention, the dose of supplementation and the nutritional situation (p 274 ANCOVA= 0.054; <0.001 and <0.007) respectively. After stratifying the sample according to the 275 effect modifiers identified in the meta-regression ( Table 5 ) the results by duration of intervention 276 showed no significant effect when the duration was short (1 to 3 weeks) (β = 0.02; CI 95% -0.03 to 277 0.07). Nevertheless, a positive effect was shown when Zn intake was provided over medium (4 to 278 20 weeks)( β = 0.09; CI 95% 0.06 to 0.13) and long periods of time (>20 weeks) (β = 0.12; CI 95% 279 0.07 to 0.16). However these pooled β still revealed high evidence of statistically significant 280 heterogeneity (I²= 91 and 96 %) respectively. When doses of Zn ranged from 4.1 to 8 mg/day, there 281 was no significant effect of Zn intake on the serum/plasma Zn; whereas a positive effect was seen 282 when doses ranged from 8.1 to 12 mg/day (β = 0.12; CI 95% 0.09 to 0.16). For doses higher than 12 283 mg/day we found no effect. However high evidence of heterogeneity was observed (I²= from 77 to 284 96 %). When studies were categorised by nutritional situation, those studies based on healthy 285 infants and on infants at nutritional risk reported a positive association between Zn intake and 286 serum/plasma Zn status (β= 0.19; CI 95% 0.04 to 0.13 and β= 0.10; CI 95% 0.05 to 0.15) 287 respectively. However, no association was found when the nutritional situation was poor (β= 0.05; 288 CI 95% -0.02 to 0.12). Once again, the pooled β still showed high evidence of heterogeneity (I²= 289 from 95 to 99 %). Due to the high heterogeneity found in all the analyses, we decided to avoid 290 calculating the dose-response relationship between Zn intake and serum/plasma Zn status. 291 292 Discussion 293
294
Our results indicate that Zn supplementation increases serum/plasma Zn status in infants, as 295 suggested by most of the individual studies. However the results obtained in the meta-analyses were 296 highly heterogeneous. Moreover, after carrying out several subgroup analyses, the pooled β for each 297 sub analysis still showed high evidence of heterogeneity. We argue that conducting a meta-analysis 298 with such data is important in order to highlight the differences between the results of the studies The interpretation of these results should be carefully considered for a number of reasons. First, the 303 number of studies that were eligible for inclusion in this meta-analysis was small, which limited the 304 statistical power of the analyses to examine the relation between status responses to Zn 305 supplementation. Thus, the small effect size we found may be explained by the limited amount of 306 available information. Also, it is well acknowledged that when many statistical comparisons are 307 carried out, one or more might reach significance due to chance alone (Bland & Altman 1995) . It is 308 also important to consider the scientific quality of included studies. Although meta-analyses are 309 increasingly used to consolidate results from multiple studies of the same topic and to develop Network ( study was randomized, the randomization method was at least partially described, reasons for and numbers of dropouts were stated (or there were no dropouts), and the method used to assess compliance and some assessment of compliance were reported. All others studies were considered as moderate when they meet any of the above criteria or high risk of bias when they meet any of the criteria. ( > 20 weeks (n=8) 0.12 (0.07 to 0.16) 162.64 (7, < 0.00001) 96%
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By dose 1 to 4 mg (n=1) 0.04 (0.01 to 0.07) 4,1 to 8 mg (n=6) 0.04 (-0.01 to 0.09) 22.08 (5, 0.0005) 77%
8,1 to 12 mg (n=13) 0.12 (0.09 to 0.16) 341.12 (12, < 0.00001) 96%
> 12 mg (n=2) 0.02 (-0.01 to 0.05) 7.21 (1, 0.007) 86%
By Nutritional Situation
Healthy (n=9) 0.09 (0.04 to 0.13) 220.90 (8, < 0.00001) 96%
Nutritionally at risk (n=10) 0.10 (0.05 to 0.15) 615.54 (9, < 0.00001) 99%
Poor nutritional status (n=3) 0.05 (-0.02 to 0.12) 39.26 (2, < 0.00001) 95%
